Board of Directors
Zhihong Xu, Ph.D., Honorary Chairman
Dr. Zhihong Xu, an internationally recognized
leader in science and education, has been a member of
Boyalife’s Board of Directors since 2009. He served
as past president of Peking University from 1999 through
2008 as well as vice president of the Chinese Academy of
Sciences from 1992 to 2001. Dr. Xu is currently chairman of
the Chinese National Committee of UNESCO’s Man and the
Biosphere (MAB) program. He also serves as an academician at
the Chinese Academy of Sciences, professor of life sciences
at Peking University, director of the Chinese Plant
Physiology Society, professor emeritus at the University of
Hong Kong, and vice president of the China Society of
Biological Engineering. Dr. Xu has been presented with
numerous honorary degrees, including an honorary doctor of
science degree by De Montfort University (1994) and
Nottingham University (2000) in the UK, Hong Kong City
University (2001), Wasada University in Japan (2002), and
McGill University in Canada (2003), an honorary doctor of
law degree by Melbourne University in Australia (2003); and
an honorary doctorate by the University of Montreal (2004)
in Canada. In 1994, he was also named as an honorary
professor at Hong Kong University.
Chris Xu, Ph.D., Chairman
Chris
Xu, Ph.D., is the current president and chairman of Boyalife
Group, which he founded in 2009. Prior to founding Boyalife,
Dr. Xu served as a project leader at Pfizer, as a director
of research at two publicly-traded biopharmaceutical
companies and as a vice president at Founder Group, a
Chinese technology conglomerate focused on information
technology, pharmaceuticals, real estate, finance, and
commodities trading. Dr. Xu’s expertise spans several
diverse therapeutic areas, including arthritis &
inflammation, cardiovascular disease, autoimmunity, oncology
and diabetes. He has authored over forty publications and
has been recognized by numerous professional societies for
his contributions to biomedical research. Dr. Xu received
his Ph.D. in immunology from Washington University School of
Medicine (St. Louis, USA) and an executive MBA from Emory
University (Atlanta, USA).
Lisa Li, M.Sc., MBA
Lisa
Li is co-founder, president and chief executive officer of
BoyaLife Group. Prior to joining the company, Ms. Li held
managerial positions of increasing responsibility at
PepsiCo, General Mills, and SSA Global Technologies. Ms. Li
received a Bachelor’s degree from Chinese Agriculture
University (Beijing), a Master’s in Applied Statistics from
North Dakota State University (Fargo) and an MBA from the
Peking University School of Business (Beijing). Ms. Li also
serves on BoyaLife’s board of directors.
Chunming Guo, Ph.D., MBA
Dr.
Guo currently serves as Senior Vice President and Chief
Financial Officer of the Boyalife Group, and Head of the
Boyalife Genomics Group. He brings to the Boyalife team
extensive experience in corporate finance and management.
Prior to joining Boyalife, Dr. Guo served as General Manager
and Board Director for various companies with Wanhua
Chemicals Group, one of the largest chemical corporations in
China (SH:600309). Dr. Guo received a Ph.D. from Nanjing
Institute of Technology and an executive MBA from Peking
University (Beijing). Dr. Guo also serves as Board Director
for Meihua Group Co. Ltd. (SH:600873).
Ruiping Xiao, MD, Ph.D.
Prior
to joining Boyalife as Chief Scientific Officer, Head of
Boyalife Institute of Translational Medicine, Dr. Xiao
served as the laboratory director of the Receptor Signaling
Section at National Institute of Health from 1996 through
2006. Since 2006, she has served as the founding director of
the Institute of Molecular Medicine at Peking University.
Dr. Xiao served on a wide range of academic committees and
editorial boards, including New England Journal of Medicine.
Dr. Xiao obtained her MD from Tongji Medical University
(China) and her Ph.D. from the University of Maryland School
of Medicine.